Memory T cells and vaccines - PubMed (original) (raw)
Review
Memory T cells and vaccines
Mark T Esser et al. Vaccine. 2003.
Abstract
T lymphocytes play a central role in the generation of a protective immune response in many microbial infections. After immunization, dendritic cells take up microbial antigens and traffic to draining lymph nodes where they present processed antigens to naïve T cells. These naïve T cells are stimulated to proliferate and differentiate into effector and memory T cells. Activated, effector and memory T cells provide B cell help in the lymph nodes and traffic to sites of infection where they secrete anti-microbial cytokines and kill infected cells. At least two types of memory cells have been defined in humans based on their functional and migratory properties. T central-memory (T(CM)) cells are found predominantly in lymphoid organs and can not be immediately activated, whereas T effector-memory (T(EM)) cells are found predominantly in peripheral tissue and sites of inflammation and exhibit rapid effector function. Most currently licensed vaccines induce antibody responses capable of mediating long-term protection against lytic viruses such as influenza and small pox. In contrast, vaccines against chronic pathogens that require cell-mediated immune responses to control, such as malaria, Mycobacterium tuberculosis (TB), human immunodeficiency virus (HIV) and hepatitis C virus (HCV), are currently not available or are ineffective. Understanding the mechanisms by which long-lived cellular immune responses are generated following vaccination should facilitate the development of safe and effective vaccines against these emerging diseases. Here, we review the current literature with respect to memory T cells and their implications to vaccine development.
Similar articles
- The effectiveness and limitations of immune memory: understanding protective immune responses.
Campos M, Godson DL. Campos M, et al. Int J Parasitol. 2003 May;33(5-6):655-61. doi: 10.1016/s0020-7519(03)00066-3. Int J Parasitol. 2003. PMID: 12782062 Review. - Lymphocyte life-span and memory.
Sprent J, Tough DF. Sprent J, et al. Science. 1994 Sep 2;265(5177):1395-400. doi: 10.1126/science.8073282. Science. 1994. PMID: 8073282 Review. - Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues.
Ebert LM, Schaerli P, Moser B. Ebert LM, et al. Mol Immunol. 2005 May;42(7):799-809. doi: 10.1016/j.molimm.2004.06.040. Epub 2004 Nov 23. Mol Immunol. 2005. PMID: 15829268 Review. - Low expression of activation marker CD69 and chemokine receptors CCR5 and CXCR3 on memory T cells after 2009 H1N1 influenza A antigen stimulation in vitro following H1N1 vaccination of HIV-infected individuals.
Chawansuntati K, Chotirosniramit N, Sugandhavesa P, Aurpibul L, Thetket S, Kosashunhanan N, Supindham T, Kaewthip O, Sroysuwan P, Sirisanthana T, Suparatpinyo K, Wipasa J. Chawansuntati K, et al. Hum Vaccin Immunother. 2015;11(9):2253-65. doi: 10.1080/21645515.2015.1051275. Epub 2015 Jun 19. Hum Vaccin Immunother. 2015. PMID: 26091502 Free PMC article. - On immunity against infections and vaccines: credo 2004.
Zinkernagel RM, Hengartner H. Zinkernagel RM, et al. Scand J Immunol. 2004 Jul-Aug;60(1-2):9-13. doi: 10.1111/j.0300-9475.2004.01460.x. Scand J Immunol. 2004. PMID: 15238068 Review.
Cited by
- VaccineDA: Prediction, design and genome-wide screening of oligodeoxynucleotide-based vaccine adjuvants.
Nagpal G, Gupta S, Chaudhary K, Dhanda SK, Prakash S, Raghava GP. Nagpal G, et al. Sci Rep. 2015 Jul 27;5:12478. doi: 10.1038/srep12478. Sci Rep. 2015. PMID: 26212482 Free PMC article. - Modeling protective anti-tumor immunity via preventative cancer vaccines using a hybrid agent-based and delay differential equation approach.
Kim PS, Lee PP. Kim PS, et al. PLoS Comput Biol. 2012;8(10):e1002742. doi: 10.1371/journal.pcbi.1002742. Epub 2012 Oct 25. PLoS Comput Biol. 2012. PMID: 23133347 Free PMC article. - Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study.
Mestiri S, Merhi M, Inchakalody VP, Taib N, Smatti MK, Ahmad F, Raza A, Ali FH, Hydrose S, Fernandes Q, Ansari AW, Sahir F, Al-Zaidan L, Jalis M, Ghoul M, Allahverdi N, Al Homsi MU, Uddin S, Jeremijenko AM, Nimir M, Abu-Raddad LJ, Abid FB, Zaqout A, Alfheid SR, Saqr HMH, Omrani AS, Hssain AA, Al Maslamani M, Yassine HM, Dermime S. Mestiri S, et al. Front Immunol. 2023 Feb 2;14:1061255. doi: 10.3389/fimmu.2023.1061255. eCollection 2023. Front Immunol. 2023. PMID: 36817441 Free PMC article. - Evaluation of CD62L expression as a marker for vaccine-elicited memory cytotoxic T lymphocytes.
Jackson SS, Schmitz JE, Kuroda MJ, McKay PF, Sumida SM, Martin KL, Yu F, Lifton MA, Gorgone DA, Letvin NL. Jackson SS, et al. Immunology. 2005 Dec;116(4):443-53. doi: 10.1111/j.1365-2567.2005.02243.x. Immunology. 2005. PMID: 16313358 Free PMC article. - In vivo mechanisms involved in enhanced protection utilizing an Fc receptor-targeted mucosal vaccine platform in a bacterial vaccine and challenge model.
Bitsaktsis C, Babadjanova Z, Gosselin EJ. Bitsaktsis C, et al. Infect Immun. 2015 Jan;83(1):77-89. doi: 10.1128/IAI.02289-14. Epub 2014 Oct 13. Infect Immun. 2015. PMID: 25312957 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical